NTLA Intellia Therapeutics Inc

Price (delayed)

$52.42

Market cap

$3.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.04

Enterprise value

$3.91B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The company's debt fell by 3% QoQ
Intellia Therapeutics's equity has soared by 75% YoY but it has decreased by 8% from the previous quarter
The company's quick ratio fell by 29% YoY but it rose by 14% QoQ
The net income has plunged by 148% YoY and by 38% from the previous quarter
The EPS has plunged by 104% YoY and by 33% from the previous quarter

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
75.85M
Market cap
$3.98B
Enterprise value
$3.91B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.1
Price to sales (P/S)
103.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
103.4
Earnings
Revenue
$37.86M
EBIT
-$368.56M
EBITDA
-$361.51M
Free cash flow
-$264.23M
Per share
EPS
-$5.04
Free cash flow per share
-$3.53
Book value per share
$12.77
Revenue per share
$0.51
TBVPS
$16.09
Balance sheet
Total assets
$1.2B
Total liabilities
$249.03M
Debt
$71.82M
Equity
$953.75M
Working capital
$749.26M
Liquidity
Debt to equity
0.08
Current ratio
6.94
Quick ratio
6.8
Net debt/EBITDA
0.17
Margins
EBITDA margin
-954.8%
Gross margin
100%
Net margin
-973.5%
Operating margin
-965.9%
Efficiency
Return on assets
-32.7%
Return on equity
-41%
Return on invested capital
-40.4%
Return on capital employed
-34.2%
Return on sales
-973.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
0.75%
1 week
15.11%
1 month
7.53%
1 year
-65.42%
YTD
-55.67%
QTD
-27.87%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$37.86M
Gross profit
$37.86M
Operating income
-$365.67M
Net income
-$368.56M
Gross margin
100%
Net margin
-973.5%
The net income has plunged by 148% YoY and by 38% from the previous quarter
The company's operating income has shrunk by 144% YoY and by 37% QoQ
The gross profit has contracted by 27% YoY but it has grown by 15% from the previous quarter
Intellia Therapeutics's revenue has decreased by 27% YoY but it has increased by 15% QoQ

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
4.1
P/S
103.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
103.4
The EPS has plunged by 104% YoY and by 33% from the previous quarter
Intellia Therapeutics's equity has soared by 75% YoY but it has decreased by 8% from the previous quarter
The stock's P/B is 64% below its last 4 quarters average of 11.3 and 23% below its 5-year quarterly average of 5.3
The price to sales (P/S) is 60% lower than the last 4 quarters average of 257.5 but 34% higher than the 5-year quarterly average of 76.9
Intellia Therapeutics's revenue has decreased by 27% YoY but it has increased by 15% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
The ROA has contracted by 29% YoY and by 22% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 22% from the previous quarter but it has increased by 3.8% YoY
Intellia Therapeutics's ROE has decreased by 22% from the previous quarter and by 21% YoY
The ROS has contracted by 20% from the previous quarter

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
The total assets has soared by 68% YoY but it has contracted by 7% from the previous quarter
Intellia Therapeutics's total liabilities has increased by 46% YoY but it has decreased by 2% QoQ
The company's debt is 92% lower than its equity
Intellia Therapeutics's equity has soared by 75% YoY but it has decreased by 8% from the previous quarter
The debt to equity has contracted by 38% YoY but it has grown by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.